Vitafarma S.a. Pharmaceutical Import Profile — Chile (DGFT 2022–2026)

Name: Vitafarma S.a. Pharmaceutical Import Records from India — 3 Products, $1.0M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Vitafarma S.a. — Pharmaceutical Importer Profile (2026) | 3 Products, $1.0M Trade | TransData Nexus

Vitafarma S.a.

Pharmaceutical Importer · Chile · Antibiotics Focus · $1.0M Total Trade · DGFT Verified

Vitafarma S.a. is a pharmaceutical importer based in Chile with a total trade value of $1.0M across 3 products in 3 therapeutic categories. Based on 20 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Vitafarma S.a. sources from 6 verified Indian suppliers, with Aculife Healthcare Private Limited accounting for 62.9% of imports.

Vitafarma S.a. — Import Portfolio & Supplier Network

Vitafarma S.a. import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Vitafarma S.a.?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Aculife Healthcare Private Limited	$2.7M	112	62.9%
Caplin Point Laboratories Limited	$1.3M	47	31.0%
Softgel Healthcare Private Limited

What Formulations Does Vitafarma S.a. Import?

Formulation	Value	Ships
Sodium chloride 0.9% solution for iv infusion(250ML	$718.5K	36
Ciprofloxacin intravenous infusion BP	$254.4K	6
Clarithromycin for oral suspension USP 250MG/5ML	$248.9K	6
Clarithromycin for oral suspension USP	$200.0K	4
Metronidazole intravenous infusion BP	$200.0K	4
Sodium chloride 0.9% solution for iv infusion(250ML)	$179.8K	13
Sodium chloride 0.9% solution for iv infusion (10ML	$177.2K	6
Linezolid i.v. injection # linestar(300ML)	$150.0K	3
Haloperidol decanoate injection 50MG/ML	$137.3K	4
Linezolid i.v. injection # linestar(300ML	$130.5K	3
Sodium chloride 0.9% solution for iv infusion(10ML)	$118.8K	4
Sodium chloride 0.9% solution for iv infusion (250ML)	$109.5K	3
Metronidazole intravenous infusion BP (0.5% w/v) nirmet 100	$105.4K	3
Metronidazole intravenous infusion BP (0.5% w/v) nirmet 100 ML	$100.0K	2
Loratadine oral solution USP 5MG/5ML	$98.1K	6

Vitafarma S.a. imports 45 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Clarithromycin	Antibiotics	$500.0K	10	0.5%	14
2	Linezolid	Advanced Antibiotics	$350.0K	7	0.9%	17
3	Lactulose	Gastrointestinal	$150.0K	3	1.1%	10

Vitafarma S.a. imports 3 pharmaceutical products across 3 categories into Chile totaling $1.0M.

Vitafarma S.a. — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Vitafarma S.A. is a pharmaceutical importer and distributor based in Santiago, Chile. Established as a subsidiary of Reutter S.A., a company with over a century of experience in the importation and commercialization of raw materials and medications, Vitafarma focuses on providing high-quality pharmaceutical products to healthcare institutions and pharmacies across Chile. (reutter.cl) The company operates under the regulatory framework set by the Chilean Ministry of Health, ensuring compliance with national standards for pharmaceutical distribution.

2Distribution Network

Vitafarma S.A. maintains its primary operations at Avenida Lo Echevers 891, Quilicura, Santiago, Chile. While specific details about additional warehouse locations and logistics capabilities are not publicly disclosed, the company's strategic location in Santiago positions it effectively to serve the entire Chilean market. This centralization likely facilitates efficient distribution and logistics operations, enabling timely delivery of pharmaceutical products to various regions within the country.

3Industry Role

In Chile's pharmaceutical supply chain, Vitafarma S.A. functions primarily as a wholesaler and distributor. By importing finished pharmaceutical formulations from international suppliers, including India, and distributing them to local healthcare providers, pharmacies, and hospitals, Vitafarma plays a crucial role in ensuring the availability of essential medications throughout the country. This position underscores its importance in bridging the gap between international pharmaceutical manufacturers and the Chilean healthcare system.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Vitafarma S.a.

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Vitafarma S.A. exhibits a high degree of sourcing concentration, with 100% of its pharmaceutical imports originating from India. This exclusive reliance on a single source country indicates a strategic choice to leverage India's robust pharmaceutical manufacturing capabilities and cost advantages. However, this concentration also introduces potential risks, such as exposure to supply chain disruptions, regulatory changes, or geopolitical issues affecting India. The company's consistent import activity, with 20 shipments recorded, suggests a stable and ongoing relationship with its Indian suppliers, which may mitigate some of these risks.

2Supply Chain Resilience

The resilience of Vitafarma S.A.'s supply chain is closely tied to its exclusive sourcing from India. While this strategy allows for streamlined procurement and potential cost efficiencies, it also makes the company vulnerable to disruptions in Indian manufacturing or export processes. The lack of publicly available information on backup suppliers or alternative sourcing strategies indicates a potential area for improvement in diversifying the supply chain to enhance resilience. Additionally, the company's focus on finished pharmaceutical formulations imported from India suggests a reliance on the quality and regulatory compliance of Indian manufacturers. Ensuring that these suppliers adhere to international standards, such as WHO GMP, is essential for maintaining product quality and compliance with Chilean regulations.

Importing Pharmaceuticals into Chile — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Chile

1Regulatory Authority & Framework

In Chile, the regulation of pharmaceutical products is overseen by the Public Health Institute (Instituto de Salud Pública, ISP), an autonomous public service under the Ministry of Health (MINSAL). The ISP is responsible for defining and controlling regulations governing the import, clearance, export, production, and manufacturing of pharmaceutical products and medical devices. (britcham.cl) The primary legislation governing pharmaceutical imports is Decree No. 3, which establishes the National System of Control of Pharmaceutical Products for Human Use. (wipo.int) This decree outlines the requirements for the importation, registration, and distribution of pharmaceutical products in Chile.

2Import Licensing & GMP

To import pharmaceutical products into Chile, companies must obtain an import license from the ISP. This license authorizes the importation, distribution, and use of pharmaceutical products within the country. (prs.cl) Additionally, the ISP requires that imported pharmaceutical products comply with Good Manufacturing Practice (GMP) standards. Recognized certifications include EU GMP, WHO GMP, and PIC/S. Importers must ensure that their suppliers hold valid GMP certifications to meet these regulatory requirements.

Quality & Labeling

Vitafarma S.a. — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Vitafarma S.A. focuses on importing pharmaceutical products in the therapeutic categories of antibiotics, advanced antibiotics, and gastrointestinal medications. This strategic focus aligns with the significant demand for these medications in Chile, driven by the prevalence of infectious diseases and gastrointestinal disorders. By concentrating on these areas, Vitafarma aims to address critical healthcare needs and establish a strong presence in essential therapeutic segments.

2Sourcing Profile

Vitafarma S.A. primarily sources generic pharmaceutical formulations from India, leveraging the country's extensive manufacturing capabilities and cost advantages. The company's procurement strategy emphasizes finished pharmaceutical products, ensuring that they meet the quality and regulatory standards required for the Chilean market. This approach allows Vitafarma to offer a diverse range of medications while maintaining a focus on quality and compliance.

3Market Positioning

Based on its product mix, Vitafarma S.A. serves multiple segments of the Chilean pharmaceutical market, including retail pharmacies, hospitals, and government tenders. By providing a range of essential medications, the company positions itself as a key supplier to various healthcare providers, contributing to the overall accessibility and availability of critical pharmaceutical products in the country.

Seller's Guide — How to Become a Supplier to Vitafarma S.a.

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with Vitafarma S.A., especially those offering high-quality generic formulations that meet international GMP standards. Potential gaps in Vitafarma's current sourcing include the need for diversification in supplier relationships to enhance supply chain resilience and the potential for expanding into additional therapeutic categories to meet evolving market demands.

2Requirements & Qualifications

Indian exporters seeking to supply Vitafarma S.A. must ensure that their pharmaceutical products comply with Chilean regulatory requirements, including obtaining the necessary import licenses from the ISP. Products must adhere to recognized GMP standards, such as EU GMP, WHO GMP, or PIC/S certifications. Additionally, exporters must ensure that their products meet Chilean labeling requirements, including Spanish language labeling and compliance with batch testing and stability study protocols.

3How to Approach

Frequently Asked Questions — Vitafarma S.a.

What products does Vitafarma S.a. import from India?

Vitafarma S.a. imports 3 pharmaceutical products across 3 categories. Top imports: Clarithromycin ($500.0K), Linezolid ($350.0K), Lactulose ($150.0K).

Who supplies pharmaceuticals to Vitafarma S.a. from India?

Vitafarma S.a. sources from 6 verified Indian suppliers. The primary supplier is Aculife Healthcare Private Limited (62.9% of imports, $2.7M).

What is Vitafarma S.a.'s total pharmaceutical import value?

Vitafarma S.a.'s total pharmaceutical import value from India is $1.0M, based on 20 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Vitafarma S.a. focus on?

Vitafarma S.a. imports across 3 categories. The largest: Antibiotics (50.0%), Advanced Antibiotics (35.0%), Gastrointestinal (15.0%).

Get Full Vitafarma S.a. Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.